Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts

被引:51
作者
Carlin, Sean [1 ,2 ]
Khan, Nahida [1 ]
Ku, Thomas [1 ]
Longo, Valerie A. [1 ]
Larson, Steve M. [1 ]
Smith-Jones, Peter M. [1 ]
机构
[1] Mem Sloan Kettering Canc Serv, Dept Radiol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Serv, Dept Med Phys, New York, NY USA
来源
PLOS ONE | 2010年 / 5卷 / 05期
基金
美国国家卫生研究院;
关键词
RADIOLABELED MONOCLONAL-ANTIBODIES; RENAL-CELL CARCINOMA; IN-VITRO; MODELING ANALYSIS; INTRINSIC MARKER; POOR-PROGNOSIS; SOLID TUMORS; LUNG-CANCER; NECK-CANCER; NUDE-MICE;
D O I
10.1371/journal.pone.0010857
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Carbonic anhydrase IX (CAIX) is a membrane spanning protein involved in the enzymatic regulation of tumor acid-base balance. CAIX has been shown to be elevated in a number of hypoxic tumor types. The purpose of this study was to determine the efficiency of intact and IgG fragments of cG250 to target CAIX in vivo in a hypoxic tumor model. Methodology/Principal Findings: Conventional biodistribution studies were performed with In-111-DO3A-cG250, In-111-DO3A-F(ab')(2)-cG250 and In-111-DO3A-Fab-cG250. Additional ex vivo analysis of the tumor was performed with markers for tumor hypoxia, blood perfusion and endogenous CAIX expression. All four data sets were digitally correlated to determine the optimal agent for determining hypoxia in a HT29 colon cancer xenograft. The HT29 human colorectal tumor xenografts show strong CAIX expression in hypoxic areas of poor blood perfusion. The intact IgG had an initial high focal uptake at the periphery of these hypoxic regions and penetration into the areas of highest CAIX expression over the 7-day study period. The lower molecular weight antibody fragments had a faster uptake into areas of high CAIX expression, but had a much lower absolute uptake at the optimal imaging times. Conclusions/Significance: For the clinical detection of hypoxia induced CAIX using cG250 antibody based agents, imaging with the intact IgG at 7 days post injection would allow for the most sensitive and accurate detection of CAIX.
引用
收藏
页数:9
相关论文
共 37 条
  • [1] BUCHEGGER F, 1983, J EXP MED, V158, P413, DOI 10.1084/jem.158.2.413
  • [2] Bui MHT, 2003, CLIN CANCER RES, V9, P802
  • [3] Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma
    Chia, SK
    Wykoff, CC
    Watson, PH
    Han, C
    Leek, RD
    Pastorek, J
    Gatter, KC
    Ratcliffe, P
    Harris, AL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3660 - 3668
  • [4] Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma
    Chrastina, A
    Závada, J
    Parkkila, S
    Kaluz, T
    Kaluzová, M
    Rajcáni, J
    Patorek, J
    Pastoreková, S
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (06) : 873 - 881
  • [5] Colcher D, 1998, Q J NUCL MED, V42, P225
  • [6] Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses:: a phase I trial
    Divgi, Chaitanya R.
    Pandit-Taskar, Neeta
    Jungbluth, Achim A.
    Reuter, Victor E.
    Gonen, Mithat
    Ruan, Shutian
    Pierre, Christine
    Nagel, Andrew
    Pryma, Daniel A.
    Humm, John
    Larson, Steven M.
    Old, Lloyd J.
    Russo, Paul
    [J]. LANCET ONCOLOGY, 2007, 8 (04) : 304 - 310
  • [7] Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas
    Driessen, A
    Landuyt, W
    Pastorekova, S
    Moons, J
    Goethals, L
    Haustermans, K
    Nafteux, P
    Penninckx, F
    Geboes, K
    Lerut, T
    Ectors, N
    [J]. ANNALS OF SURGERY, 2006, 243 (03) : 334 - 340
  • [8] DVORAK HF, 1988, AM J PATHOL, V133, P95
  • [9] FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
  • [10] FUJIMORI K, 1989, CANCER RES, V49, P5656